Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused by E. Coli

Antibiotics
Beata Maria Zalewska-Piątek, Rafał Janusz Piątek

Abstract

Urinary tract infections (UTIs) are regarded as one of the most common bacterial infections affecting millions of people, in all age groups, annually in the world. The major causative agent of complicated and uncomplicated UTIs are uropathogenic E. coli strains (UPECs). Huge problems with infections of this type are their chronicity and periodic recurrences. Other disadvantages that are associated with UTIs are accompanying complications and high costs of health care, systematically increasing resistance of uropathogens to routinely used antibiotics, as well as biofilm formation by them. This creates the need to develop new approaches for the prevention and treatment of UTIs, among which phage therapy has a dominant potential to eliminate uropathogens within urinary tract. Due to the growing interest in such therapy in the last decade, the bacteriophages (natural, genetically modified, engineered, or combined with antibiotics or disinfectants) represent an innovative antimicrobial alternative and a strategy for managing the resistance of uropathogenic microorganisms and controlling UTIs.

References

Apr 1, 1975·Journal of Virology·W BesslerS Stirm
Jan 1, 1973·Annual Review of Microbiology·A A Lindberg
Jun 1, 1965·Journal of General Microbiology·I W Sutherland, J F Wilkinson
Sep 1, 1995·Obstetrical & Gynecological Survey·M S Mikhail, A Anyaegbunam
Nov 1, 1994·Journal of Clinical Microbiology·W Nimmich
Jan 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R IkäheimoP H Mäkelä
May 24, 2000·The Journal of Infectious Diseases·T A Russo, J R Johnson
Dec 15, 2000·Journal of Bacteriology·F TétartH M Krisch
Feb 15, 2001·The Journal of Infectious Diseases·W E Stamm, S R Norrby
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·A SulakvelidzeJ G Morris
Feb 24, 2001·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·M Nuutinen, M Uhari
Jul 5, 2003·Science·Gregory G AndersonScott J Hultgren
Sep 19, 2003·Applied Microbiology and Biotechnology·Y TanjiH Unno
Jan 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Sheryl S JusticeScott J Hultgren
Mar 26, 2004·Nature Reviews. Microbiology·James B KaperHarry L Mobley
Apr 6, 2004·FEMS Microbiology Letters·Ian W SutherlandKaren Tait
Apr 28, 2004·FEMS Microbiology Reviews·Markus G Weinbauer
Oct 27, 2004·Infection and Immunity·Jennifer A SnyderHarry L T Mobley
May 26, 2005·The Journal of Antimicrobial Chemotherapy·Naseem MushtaqPeter W Taylor
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·Anne Bruttin, Harald Brüssow
Feb 3, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CapparelliD Iannelli
Jul 4, 2006·American Journal of Infection Control·David L Paterson
Nov 23, 2006·Antimicrobial Agents and Chemotherapy·Ryohei WatanabeKeizo Yamaguchi
Jun 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·Timothy K Lu, James J Collins
Dec 21, 2007·PLoS Medicine·David A RosenScott J Hultgren
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J Garau
May 17, 2008·Experimental and Molecular Pathology·Travis J WilesMatthew A Mulvey
Aug 12, 2008·Current Pharmaceutical Biotechnology·J Azeredo, I W Sutherland
Oct 24, 2008·Current Infectious Disease Reports·Paola Lichtenberger, Thomas M Hooton
Feb 13, 2010·International Journal of Antimicrobial Agents·Niels HøibyOana Ciofu
Jan 1, 2009·Current Pharmaceutical Biotechnology·Lawrence D Goodridge
Mar 17, 2010·Antimicrobial Agents and Chemotherapy·Matthew G Blango, Matthew A Mulvey
Apr 8, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Hassib Narchi, Muhaned Al-Hamdani
Jun 4, 2010·The Journal of Biological Chemistry·James E ThompsonIan S Roberts
Jun 10, 2010·FEMS Immunology and Medical Microbiology·Louise CarsonBrendan F Gilmore
Nov 11, 2010·Pharmaceutical Research·Jean-Paul PirnayRevaz Adamia
Nov 18, 2010·The Journal of Antimicrobial Chemotherapy·Benjamin A RogersDavid L Paterson
Dec 9, 2010·Nature Reviews. Urology·Betsy Foxman

❮ Previous
Next ❯

Citations

Apr 28, 2021·Annals of Clinical Microbiology and Antimicrobials·Zahra CheginiAref Shariati
May 1, 2021·Pharmaceuticals·Beata Zalewska-Piątek, Rafał Piątek
Jul 6, 2021·Frontiers in Cellular and Infection Microbiology·Mengting GuoYaxian Yan
Aug 28, 2021·International Journal of Molecular Sciences·Magdalena PodlachaAlicja Węgrzyn

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Michael L Wilson, Loretta Gaido
Expert Opinion on Emerging Drugs
Florian M E WagenlehnerKurt G Naber
Primary Care
Pat F BassCharlene K Mitchell
Expert Review of Anti-infective Therapy
Florian M E Wagenlehner, Kurt G Naber
© 2022 Meta ULC. All rights reserved